News

NIH Awards Ceres Nanosciences $8.2M for Wastewater-Based COVID-19 Surveillance

Ceres Nanosciences announced it has been awarded an $8.2 million contract from the National Institutes of Health’s Rapid Acceleration of Diagnostics Initiative. The funding will support the development and implementation of wastewater-based surveillance systems for COVID-19.

Manassas, Virginia-based Ceres plans to develop surveillance systems using its Nanotrap particle technology at a network of sites, with an emphasis on underserved and vulnerable populations.

In a statement, Ceres noted that wastewater surveillance can be used to monitor trends in SARS-CoV-2 infection at a population level, but that “widespread implementation has been stymied by the lack of a sensitive, rapid, high-throughput viral concentration method.”

The firm’s Nanotrap Magnetic Virus Particles can capture and concentrate viruses directly from raw sewage prior to RNA extraction, according to Ceres, and this workflow can be adapted for small- and large-scale surveillance systems.

As part of the new funding, Ceres will work with researchers at Emory University to develop and implement a wastewater-based COVID-19 surveillance system in the metro-Atlanta area “with a focus on use cases for underserved and vulnerable populations,” such as correctional facilities, low-income neighborhoods, and long-term care facilities, the firm said.

Christine Moe, a wastewater infectious disease researcher at Emory, said that the collaboration between Ceres and the university will generate “robust evidence” to support the US Center for Disease Control and Prevention’s objective of developing a national wastewater surveillance system that “meets the information needs of city, county, and state decision makers to effectively respond to the COVID-19 pandemic across multiple use cases in underserved community settings.”

In parallel to this collaboration, Ceres will also be identifying and launching a network of “centers of excellence” for high-throughput wastewater-based COVID-19 surveillance.

Ben Lepene, Ceres’s chief technology officer, noted that researchers from the University of California, San Diego recently described a Nanotrap particle high-throughput method for wastewater surveillance that can process more than 100 samples in a day “with an ability to detect one asymptomatic infected individual in a building with 415 residents.” The firm expects to identify additional sites in the US to implement similar approaches.

Last year, Ceres was awarded $6.6 million from RADx to increase the manufacturing capacity of its Nanotrap Magnetic Virus Particles. The Nanotrap technology has also been also utilized for SARS-CoV-2 and Lyme disease diagnostics, as well as in liquid biopsy applications.

Recent News

02/20/2025

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

“Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return

02/11/2025

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,  announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI). This collaboration seeks to develop the first intranasal therapy for mild traumatic brain injury (mTBI) aka concussion, creating a comprehensive trigger-to-treat

02/11/2025

Children’s National and Compremium partner on pediatric medtech innovation

Children’s National Hospital announced a new collaboration with Swiss medical device company Compremium AG to co-develop and commercialize innovative medical technologies designed specifically for pediatric patients. This first-of-its-kind agreement leverages the expertise of Children’s National in pediatric healthcare innovation and Compremium’s non-invasive platform technology for diagnosing pressure-related conditions, accelerating advancements in pediatric medicine. Diagnosing pressure-related